|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an
educational grant from
BioCryst
Description:
Hereditary angioedema (HAE) is a rare autosomal dominant condition
characterized by recurrent attacks of edema at different locations
of the body. This potentially life-threatening disease affects
approximately 1 in 67,000 individuals, with no identified
differences in sex or ethnicity. HAE is characterized by recurrent
edema attacks and cutaneous attacks can be disabling. The skin,
gastrointestinal tract, and upper airways are most commonly affected
and with a persistent risk to the patient of acute events of
laryngeal swelling that may prove fatal if not treated in a timely
manner. Angioedema in general can be confused with cellulitis,
Graves disease, blepharochalasis, eosinophilic fasciitis, or
amyloidosis which can lead to delays in diagnosis, and inappropriate
treatment poses the risk of adverse events, unnecessary surgical
interventions, a higher burden of misery, and a potentially higher
rate of morbidity and mortality. Fortunately for patients with HAE,
novel therapies have recently become available in the past few years
that have shown improved efficacy and safety with improved
administration methods, including oral therapy. With these new
options comes a knowledge gap among physician medical directors,
pharmacists, immunologists, and nurse case managers as the treatment
paradigm is growing.
Upon completion of this
activity, participants will be able to:
-
Review
the clinical and economic burden of hereditary angioedema (HAE)
and its impact on quality of life for patients with HAE
-
Distinguish HAE types I and II, their pathophysiology, and the
burden of disease
-
Evaluate
the importance of early diagnosis and prompt intervention,
including prophylaxis and on-demand acute medications
-
Differentiate current and emerging treatments prophylactic
therapies for HAE based on their mechanism of action, routes of
administration, and latest clinical efficacy and safety data
-
Analyze
recent real-world data on the evolving role of oral therapy in
the prevention of HAE attacks
-
Discuss
the role of managed care professionals in the development of
evidence-based clinical protocols in HAE
Faculty:
Marc Riedl, MD, MS
Professor of Medicine
HAE Community Endowed Chair
Clinical Director – US HAEA Angioedema Center
Clinical Service Chief – Division of Allergy & Immunology
University of California, San Diego
mriedl@health.ucsd.edu
Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance,
independence, objectivity, and scientific rigor in all of their
activities. All faculty participating in this activity are required
to disclose to NAMCP/AAMCN any financial relationships with
ineligible companies. NAMCP/AAMCN in turn discloses all relevant
financial conflicts to the learners. NAMCP/AAMCN disclosure policy
adheres to The Standards for Integrity and Independence in
Accredited Continuing Education. All relevant conflicts of interest
have been mitigated prior to the commencement of the activity. See
below for conflicts of interest.
Disclosures (Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Riedl has served as a consultant for Astria, Biocryst, Biomarin,
Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia, Kalvista,
Pfizer, Pharming, Pharvaris, Regeneron, Sanofi, and Takeda. He has
received grant/research support from Biocryst, Biomarin, CSL Behring,
Ionis, Kalvista, Pharvaris, Takeda. All relevant financial
relationships have been mitigated.
Planning Committee Disclosures (Relevant Financial Relationships
with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an
ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an
ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship
with an ineligible company to disclose.
NAMCP and/or the presenter has copyright or has received permissions
for use of materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring
material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
NAMCP and/or this website do not provide medical advice, diagnosis,
or treatment. NAMCP does not endorse or imply endorsement of the
content on any linked website. This website is to be used as an
informational resource. With any health-related concern, consult
with your physician or healthcare professional.
This activity is supported by an educational grant from
BioCryst
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |